Last update June 26, 2022

Tranylcypromine Sulfate

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

Monoamine oxidase inhibitor antidepressant (MAOI) with action and uses similar to phenelzine. Oral administration once or twice daily.

At the date of the last update we did not find any published data on its excretion in breast milk.

Its wide volume of distribution (DrugBank acc.2022, Mallinger 1986) make it highly unlikely that significant quantities will pass into breast milk.

Monitor sedation and/or irritability in the infant.

A 15-day-old infant with serious malformations and whose mother was taking tranylcypromine, pimozide, diazepam, and alprazolam since pregnancy had problems with abdominal distention and food intolerance. (Kennedy 2017)

May cause increased prolactin. (Price 1985)

Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable, especially during the neonatal period and in the event of prematurity.

See below the information of this related product:

  • Maternal Depression (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)


Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Tranylcypromine Sulfate is also known as

Tranylcypromine Sulfate in other languages or writings:


Tranylcypromine Sulfate belongs to these groups or families:


Main tradenames from several countries containing Tranylcypromine Sulfate in its composition:


Variable Value Unit
Molecular weight 365 daltons
VD 1.1 - 5.7 l/Kg
pKa 9.62 -
Tmax 1.5 ± 0.9 hours
2. 45 (1.5 - 3.2) hours


  1. DRUGBANK ONLINE. 2006 - Consulted on Jan. 9, 2024 Full text (link to original source)
  2. FDA. Tranylcypromine (Parnate). Drug Summary. 2018 Full text (in our servers)
  3. Kennedy D, Webster WS, Hill M, Ritchie HE. Abnormal pregnancy outcome associated with high-dose maternal tranylcypromine therapy: Case report and literature review. Reprod Toxicol. 2017 Apr;69:146-149. Abstract
  4. Mallinger AG, Edwards DJ, Himmelhoch JM, Knopf S, Ehler J. Pharmacokinetics of tranylcypromine in patients who are depressed: relationship to cardiovascular effects. Clin Pharmacol Ther. 1986 Oct;40(4):444-50. Abstract
  5. Price LH, Charney DS, Heninger GR. Effects of tranylcypromine treatment on neuroendocrine, behavioral, and autonomic responses to tryptophan in depressed patients. Life Sci. 1985 Sep 2;37(9):809-18. Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM